About this Series

For nearly two decades, tyrosine kinase inhibitors (TKIs) have been standard therapy for patients with chronic myeloid leukemia (CML). The first TKI, imatinib, was approved by the US Food and Drug Administration in 2001 and had a dramatic effect on CML mortality, making imatinib standard treatment for chronic-phase CML.

As research has progressed, additional therapeutic agents, including second- and third-generation TKIs and a generic imatinib, have increased the number of treatment options, making the optimal therapy for patients with chronic-phase CML less straightforward.

The CML team at MD Anderson Cancer Center in Houston, led by Dr Jorge Cortes, addresses emerging issues in current management of chronic-phase CML, focusing on the optimal choice of front-line therapy, the not-so-easy role of generic imatinib, patient compliance with TKI use, and successful methods to electively stop TKI therapy in select patients.

Show More

Who's Who
{{#each bp-whos-who.people}}
{{{name}}} {{{addComma prof}}}
{{#if disclosureTitle }} Disclosure
More on Chronic Myeloid Leukemia